Immunoglobulin G

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 12:05, January 26, 2022 by Notjusttired (talk | contribs) (move IgG3 higher, expand)

Immunoglobulin G or IgG is a the most common class of antibody in human blood, making up 80% of the antibodies, and is also found in tissue spaces.[1] IgG antibodies bind to phagocytes, have γ (gamma) heavy chains and can cross the placenta.[1] The IgG class consists of IgG1, IgG2, IgG3 and IgG4.[2]

Function[edit | edit source]

IgG is the only antibody that can cross the placenta, giving unborn and new born babies protection against contagious diseases and other infections.[1]

The typical four-chain structure of a generic antibody monomer, for example IgG.
Source: 18.1 Overview of Specific Adaptive Immunity". Microbiology. OpenStax.[1]

IgG3[edit | edit source]

IgG3 or immunoglobulin G3 level along with other factors was found to be predictive of the likelihood of developing Long COVID after SARS-CoV-2 infection by Cervia et al. (2022).[3]

ME/CFS[edit | edit source]

IVIG or intravenous immunoglobulin G is a treatment that has been investigated for ME/CFS, with positive results shown for some patients.

Fibromyalgia[edit | edit source]

In 2021, Goebel et al. published research showing that fibromyalgia may be an immune system disease mediated by IgG; in an animal study on mice they found that the mice developed pain and cold intolerance symptoms consistent with fibromyalgia after receiving IgG from the blood of patients with fibromyalgia.[4]

Long COVID[edit | edit source]

Cervia et al. (2022) found that both IgG3 and IgM, when combined with other factors including age, presence of five symptoms (fever, fatigue, cough, shortness of breath, gastrointestinal symptoms during COVID-19 infection), acted as biomarkers to predict who would develop Long COVID after SARS-CoV-2 infection.[3]

Notable studies[edit | edit source]

  • 2022, Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome[3] - (Full text)

News and articles[edit | edit source]

"Andersson and his colleagues harvested blood from 44 people with fibromyalgia and injected purified antibodies from each of them into different mice. The mice rapidly became more sensitive to pressure and cold, and displayed reduced grip strength in their paws. Animals injected with antibodies from healthy people were unaffected."[5]

Prof Camilla Svensson from the Karolinska Institute in Sweden, who was also involved in the study, said:

"Antibodies from people with fibromyalgia living in two different countries, the UK and Sweden, gave similar results, which adds enormous strength to our findings."[5]

Notable studies[edit | edit source]

  • 2021, Passive transfer of fibromyalgia symptoms from patients to mice[4]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 1.2 1.3 Parker, Nina; Schneegurt, Mark; Tu, Anh-Hue Thi; Lister, Philip; Forster, Brian M. (November 1, 2016). "18.1 Overview of Specific Adaptive Immunity". Microbiology. OpenStax. Houston, Texas. Retrieved July 9, 2021.
  2. https://primaryimmune.org/about-primary-immunodeficiencies/specific-disease-types/igg-subclass-deficiency
  3. 3.0 3.1 3.2 https://www.nature.com/articles/s41467-021-27797-1
  4. 4.0 4.1 Goebel, Andreas; Krock, Emerson; Gentry, Clive; Israel, Mathilde R.; Jurczak, Alexandra; Urbina, Carlos Morado; Sandor, Katalin; Vastani, Nisha; Maurer, Margot (July 7, 2021). "Passive transfer of fibromyalgia symptoms from patients to mice". The Journal of Clinical Investigation. 131 (13). doi:10.1172/JCI144201. ISSN 0021-9738.
  5. 5.0 5.1 "Fibromyalgia may be a condition of the immune system not the brain – study". the Guardian. July 1, 2021. Retrieved July 8, 2021.